For use in: Dogs only
Vetoryl Capsules are the only FDA approved pharmaceutical for the treatment of Pituitary-Dependent Hyperadrenocorticism (PDH) and Adrenal-Dependent Hyperadrenocorticism (ADH) in dogs.
- Vetoryl Capsules contain trilostane, which selectively, and reversibly, inhibits the enzyme 3ß-hydroxysteroid dehydrogenase, which is involved in the synthesis of several steroids including cortisol and aldosterone.
- At recommended dose rates, Vetoryl Capsules tend to have a more selective effect on glucocorticoid production, however the potential inhibition of aldosterone must always be borne in mind by the attending clinician.
- Vetoryl Capsules reduce circulating cortisol levels, leading to improvement in many of the clinical signs of HAC.
Vetoryl Capsules provide flexible and accurate dosing with five strengths (5 mg, 10 mg, 30 mg, 60 mg and 120 mg capsules), helping to restore the dog's vitality by reducing the clinical signs associated with HAC.